What We Do
1 – TID
- Identify and validate structural proteins
- Characterize target druggability through in silico and experimental data
2 – M2H
MolecuLern TO HIT
- Match targets with MolecuLern
3 – HV
- Validate binding pocket and property enumeration
4 – H2L
HIT TO LEAD
- Iterative screening, Med-Chem tractability, and lead identification
5 – LO
- NCEs to synthesis
- SAR to lead selection
6 – CN
Precise: Our training set of real empirical/wet lab data allows us to cover the spectrum of protein/small molecule interactions to discover targetable hot spots, minimizing the “hit-and-miss” of traditional drug discovery.
Accelerated: Cutting-edge platform supported by decades of work and over 5 years of AI/ML development to discover new medicines with previously impossible speed and accuracy.
Validated: MolecuLern is trained on hundreds of 3D structures, from PDB and DeepMind AlphaFold protein targets, screened against our IP rich proprietary fragment and NCE library.
Other Solid Tumors
Diseases – ALS/AD
INTEGRATED DRUG DISCOVERY PLATFORM
Biolexis utilizes the MolecuLern platform to discover and develop our own NCEs. Our pipeline projects are available for licensing or partnering.
NCE DISCOVERY AND DEVELOPMENT
MolecuLern can discover and develop innovative, IP-rich NCEs targeting any class of proteins. Our training set of real empirical/wet lab data allows us to cover the spectrum of protein/small molecule interactions and discover targetable hot spots on target proteins. MolecuLern takes you from simple concept to drugable NCEs in a fraction of the time.
858 S Auto Mall Dr. #102
American Fork, UT 84003
Ph: 385-289-1282 firstname.lastname@example.org